West Pharmaceutical Services (WST) Price & Analysis

1 Followers

WST Stock Chart & Stats

$5300.00

$0.00(0.00%)

At close: Jul 24 4:00 PM EDT

$5300.00

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$4,435.00 - $5,300.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

$540.00B

Enterprise Value$26.10B

Total Cash (Recent Filing)$464.10M

Total Debt (Recent Filing)$305.00M

Price to Earnings (P/E)46.0

Beta-0.55

Next Earnings

Feb 18, 2027

EPS Estimate

42.97

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)8.97

Shares Outstanding70,375,760

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio33.99

Price to Book (P/B)6.26

Price to Sales (P/S)6.47

P/FCF Ratio42.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$9,028.83

Price Target Upside70.36% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)175.77

Revenue Forecast (FY)$64.12B

Bulls Say, Bears Say

Bulls Say

High-Value Product LeadershipHigh-value components are central to West’s revenue base and benefit from biologics, GLP-1 therapies, and qualified customer applications. Their critical role in injectable containment can support repeat demand, stronger product mix, and durable competitive positioning over the next several quarters.

Raised Growth And Margin OutlookManagement’s higher revenue outlook and planned margin expansion indicate strong underlying demand and operating execution rather than reliance solely on temporary volume. Improved mix, pricing, plant performance, and leverage can strengthen earnings power and support reinvestment in growth.

Conservative Balance Sheet And Cash GenerationLow leverage gives West meaningful financial flexibility across industry cycles and reduces pressure from interest obligations. Healthy operating and free cash flow provide internal funding for capacity expansion, customer support, dividends, and other strategic priorities without depending heavily on additional debt.

Bears Say

West Vantage Portfolio TransitionThe West Vantage decline shows that portfolio transition is currently offsetting gains from new, higher-value drug-handling programs. Muted growth expected this year and next could weigh on consolidated momentum while replacement projects ramp and legacy revenue continues to roll off.

Uneven Cash ConversionWorking-capital investment is absorbing more cash even as operations expand, reducing near-term cash conversion and limiting the portion of earnings available for discretionary uses. If receivables and inventory remain elevated, funding capacity for buybacks, dividends, or expansion could be less efficient.

Delivery Device And SmartDose HeadwindsThe delivery-device business has uneven quarterly performance, and the SmartDose 3.5 divestiture removes an existing revenue stream. These factors can make reported growth less consistent and require new product adoption and customer programs to offset the resulting portfolio headwind.

West Pharmaceutical Services News

West Pharmaceutical price target raised to $500 from $420 at TD Cowen

TD Cowen raised the firm’s price target on West Pharmaceutical (WST) to $500 from $420 and keeps a...

1d ago

WST

West Pharmaceutical price target raised to $480 from $440 at Evercore ISI

Evercore ISI analyst Daniel Markowitz raised the firm’s price target on West Pharmaceutical (WST) to $480 from $440...

1d ago

WST

West Pharmaceutical price target raised to $494 from $412 at Citi

Citi raised the firm’s price target on West Pharmaceutical (WST) to $494 from $412 and keeps a Buy...

1d ago

WST

West Pharmaceutical price target raised to $500 from $440 at Barclays

Barclays raised the firm’s price target on West Pharmaceutical (WST) to $500 from $440 and keeps an Overweight...

1d ago

WST

West Pharmaceutical ups FY26 adjusted EPS view to $9.38-$9.48 from $8.85-$9.05

Consensus $8.96. Raises FY26 revenue view to $3.41B-$3.42B from $3.35B-$3.38B, consensus $3.37B. Cuts FY26 capital expenditures view to...

2d ago

WST

West Pharmaceutical reports Q3 EPS $2.66, consensus $2.20

Reports Q3 revenue $874.5M, consensus $826.55M. Michel Lagarde, President and Chief Executive Officer, commented: “I am pleased to...

2d ago

WST

West Pharmaceutical price target raised to $420 from $410 at TD Cowen

TD Cowen analyst Brendan Smith raised the firm’s price target on West Pharmaceutical (WST) to $420 from $410...

18d ago

WST

West Pharmaceutical price target raised to $440 from $400 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on West Pharmaceutical (WST) to $440 from $400 and...

24d ago

WST

West Pharmaceutical Services Raises Outlook After Strong Q3

The latest update is out from West Pharmaceutical Services ( ($WST) ). On October 29, 2026, West Pharmaceutical...

2d ago

WST

Is WST a Buy, Before Earnings?

West Pharmaceutical Services, Inc. (WST) is scheduled to report 3rd quarter earnings on 10/29/2026, before the market opens....

4d ago

WST

West Pharmaceutical Services Enhances Liquidity With New Credit Facility

West Pharmaceutical Services ( ($WST) ) has shared an update. On October 26, 2026, West Pharmaceutical Services, Inc....

5d ago

WST

West Pharmaceutical upgraded to Overweight at Morgan Stanley on durable growth

As previously reported, Morgan Stanley analyst Kallum Titchmarsh upgraded West Pharmaceutical (WST) to Overweight from Equal Weight with...

1M ago

WST

West Pharmaceutical upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Kallum Titchmarsh upgraded West Pharmaceutical (WST) to Overweight from Equal Weight with a price target...

1M ago

WST

West Pharmaceutical: Hold Rating Reiterated as Robust GLP-1 Demand Meets Fully Valued Shares; Price Target Maintained at $365

In a report released yesterday, Kallum Titchmarsh from Morgan Stanley maintained a Hold rating on West Pharmaceutical Services,...

2M ago

WST

WST FAQ

What was West Pharmaceutical Services, Inc.’s price range in the past 12 months?

West Pharmaceutical Services, Inc. lowest stock price was $4435.00 and its highest was $5300.00 in the past 12 months.

What is West Pharmaceutical Services, Inc.’s market cap?

West Pharmaceutical Services, Inc.’s market cap is $540.00B.

When is West Pharmaceutical Services, Inc.’s upcoming earnings report date?

West Pharmaceutical Services, Inc.’s upcoming earnings report date is Feb 18, 2027 which is in 110 days.

How were West Pharmaceutical Services, Inc.’s earnings last quarter?

West Pharmaceutical Services, Inc. released its earnings results on Oct 29, 2026. The company reported $49.973 earnings per share for the quarter, beating the consensus estimate of $41.35 by $8.623.

Is West Pharmaceutical Services, Inc. overvalued?

According to Wall Street analysts West Pharmaceutical Services, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does West Pharmaceutical Services, Inc. pay dividends?

West Pharmaceutical Services, Inc. does not currently pay dividends.

What is West Pharmaceutical Services, Inc.’s EPS estimate?

West Pharmaceutical Services, Inc.’s EPS estimate is 42.97.

How many shares outstanding does West Pharmaceutical Services, Inc. have?

West Pharmaceutical Services, Inc. has 70,375,760 shares outstanding.

What happened to West Pharmaceutical Services, Inc.’s price movement after its last earnings report?

West Pharmaceutical Services, Inc. reported an EPS of $49.973 in its last earnings report, beating expectations of $41.35. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of West Pharmaceutical Services, Inc.?

Currently, no hedge funds are holding shares in MX:WST

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

West Pharmaceutical Services Stock Smart Score

Neutral

Fundamentals

Return on Equity

21.08%

Trailing 12-Months

Asset Growth

-1.10%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

West Pharmaceutical Services (WST) Earnings & Revenues

Historic Earnings Reports

WST Company Deck

WST Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call was strongly positive: West exceeded Q3 revenue and earnings expectations, delivered broad-based organic growth, expanded margins significantly, raised full-year revenue and EPS guidance, and reported strong demand across HVP Components, GLP-1, biologics, and multiple geographies. The main challenges were the West Vantage decline, SmartDose 3.5 divestiture-related revenue effects, a 5% year-to-date free-cash-flow decrease, and expected moderation in HVP Delivery Device growth in Q4.View all MX:WST earnings summaries

WST Revenue Breakdown

81.07% Proprietary Products

18.93% Contract-Manufactured Products

0.00% Intersegment sales elimination

WST Stock 12 Month Forecast

Average Price Target

$9,028.83

▲(70.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4423":"$4,423","9442":"$9,442","5677.75":"$5,677.8","6932.5":"$6,932.5","8187.25":"$8,187.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9441.087615,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9028.826789145001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7552.870092,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4423,5677.75,6932.5,8187.25,9442],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5300,5618.545201153846,5937.090402307693,6255.635603461538,6574.180804615385,6892.726005769231,7211.2712069230765,7529.816408076923,7848.361609230769,8166.906810384616,8485.452011538462,8803.997212692308,9122.542413846153,{"y":9441.087615,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5300,5586.832829934231,5873.665659868462,6160.498489802692,6447.331319736923,6734.1641496711545,7020.996979605385,7307.829809539616,7594.662639473847,7881.495469408078,8168.328299342309,8455.16112927654,8741.99395921077,{"y":9028.826789145001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5300,5473.297699384615,5646.595398769231,5819.893098153846,5993.190797538462,6166.488496923077,6339.786196307692,6513.083895692307,6686.381595076923,6859.679294461539,7032.976993846154,7206.274693230769,7379.572392615384,{"y":7552.870092,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4424.479,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4424.479,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4428.499,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5105.016,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5106.294,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5108.293,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5108.293,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5300,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5300,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5300,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5300,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5300,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5300,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >